Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising new drug targets genetic Parkinson's in early trial

NCT ID NCT06602193

Ongoing Disease control Sponsor: Denali Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called BIIB122 in 50 people who have a specific genetic form of Parkinson's disease (LRRK2-PD). The main goal is to check the drug's safety and how it affects certain markers in the blood and urine over 12 weeks. Participants are randomly assigned to receive either the drug or a placebo, and neither they nor the doctors know who gets which.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LRRK2-ASSOCIATED PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 8 movement disorder Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • Cedars-Sinai Department of Neurology

    Los Angeles, California, 90048, United States

  • Evergreen Health Laboratory

    Kirkland, Washington, 98034, United States

  • Hospital Clinic de Barcelona

    Barcelona, Spain

  • Hospital Universitari General de Catalunya

    Barcelona, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitario Donostia

    Donostia / San Sebastian, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

  • IDIVAL/University Hospital Marques de Valdecilla

    Santander, Spain

  • Ichan School of Medicine at Mount Sinai/Beth Israel Downtown-Movement Disorder Center

    New York, New York, 10003, United States

  • Inland Northwest Research

    Spokane, Washington, 99202, United States

  • Movement Disorders Institute, Sheba Medical Center

    Ramat Gan, Israel

  • Parkinson's Disease and Movement Disorders Center

    Boca Raton, Florida, 33486, United States

  • Rabin Medical Center

    Petah Tikva, Israel

  • Technische Universität Dresden

    Dresden, Germany

  • Tel Aviv Medical Center

    Tel Aviv, Israel

  • Universitary Hospital La Princesa

    Madrid, Spain

  • University Hospital Tübingen

    Tübingen, Germany

  • University of California San Francisco

    San Francisco, California, 94158, United States

  • University of Lübeck

    Lübeck, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.